Last update 01 Nov 2024

Acorda Therapeutics Ireland Ltd.

Subsidiary Company|
Ireland

Overview

Tags

Nervous System Diseases
Congenital Disorders
Immune System Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Endocrinology and Metabolic Disease1
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
D1 receptor x DRDs1
Potassium channel1

Related

2
Drugs associated with Acorda Therapeutics Ireland Ltd.
Dalfampridine
Target
Potassium channel
Mechanism
Potassium channel blockers
Active Org.
Biogen Netherlands BV [+6]
Originator Org.
Acorda Therapeutics, Inc.Acorda Therapeutics, Inc.
Active Indication
Multiple Sclerosis [+1]
Inactive Indication
Cerebral Palsy [+9]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date22 Jan 2010
Levodopa hydrate
Target
D1 receptor x DRDs
Mechanism
D1 receptor agonists [+1]
Active Org.
Acorda Therapeutics Ireland Ltd. [+4]
Originator Org.
F. Hoffmann-La Roche Ltd.
Active Indication
Parkinson Disease
Inactive Indication
Asthma [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date04 Jun 1970
100 Clinical Results associated with Acorda Therapeutics Ireland Ltd.
Login to view more data
0 Patents (Medical) associated with Acorda Therapeutics Ireland Ltd.
Login to view more data
100 Deals associated with Acorda Therapeutics Ireland Ltd.
Login to view more data
100 Translational Medicine associated with Acorda Therapeutics Ireland Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
2
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Dalfampridine
 ( Potassium channel )		Multiple Sclerosis
More
Approved
Levodopa hydrate
 ( D1 receptor x DRDs )		Parkinson Disease
More
Approved
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free